RTP Mobile Logo

Interview with David J Straus, MD

Track 1: Case: A 25-year-old woman with Stage IIA nodular sclerosing classical Hodgkin lymphoma (HL) receives risk-adapted doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) therapy on the Phase II CALGB-50604 trial
Track 2: Use of chemotherapy versus combined-modality treatment for early-stage HL
Track 3: Risks and benefits of involved-field radiation therapy for patients with early-stage HL
Track 4: Case: A 19-year-old woman with bulky Stage IIA HL receives 6 cycles of ABVD
Track 5: Ongoing investigations of ABVD or brentuximab vedotin (BV) with doxorubicin/vinblastine/dacarbazine (AVD) with or without radiation therapy for newly diagnosed early-stage HL
Track 6: Perspective on potentially safer radiation therapy administration methods for early-stage HL
Track 7: Case: A 27-year-old man with nodular sclerosing Stage IVB classical HL receives front-line BV and AVD
Track 8: Design and major efficacy results from the Phase III ECHELON-1 trial evaluating BV with AVD versus ABVD as front-line therapy for advanced-stage classical HL
Track 9: ECHELON-1: Incidence and management of BV-associated neutropenia and peripheral neuropathy
Track 10: Pulmonary toxicity with bleomycin
Track 11: Estimating the risk of relapse after up-front therapy for advanced-stage HL
Track 12: Real-world analysis of cost, healthcare resource usage and supportive care for patients with HL who experience front-line therapy failure
Track 13: Case: A 40-year-old man with heavily pretreated HL experiences a prolonged response to nivolumab on a clinical trial
Track 14: Salvage therapy options
Track 15: Results of the Phase III AETHERA trial of BV as consolidation therapy after autologous stem cell transplant (ASCT) for patients with HL at risk of relapse or progression
Track 16: Efficacy of BV in combination with an anti-PD-1 immune checkpoint inhibitor for relapsed/refractory HL
Track 17: Activity of chimeric antigen receptor T-cell therapy in patients with HL
Track 18: Forecast of the future treatment of HL

Interview with Radhakrishnan Ramchandren, MD

Track 1: Case: A 29-year-old man with Stage IIIB HL receives up-front AVD and BV on a clinical trial
Track 2: Prognosis and risk of relapse with standard ABVD versus response-adapted ABVD versus BV with AVD for advanced-stage HL
Track 3: Incidence of pulmonary toxicity with bleomycin
Track 4: Quality and interpretation of PET scanning for patients receiving response-adapted therapy
Track 5: Risk of febrile neutropenia and peripheral neuropathy with BV in combination with AVD
Track 6: Clinical experience with and management of BV-associated peripheral neuropathy
Track 7: Fertility after chemotherapy for HL
Track 8: Consideration of bleomycin for older patients
Track 9: Evolution of treatment modalities in early- and advanced-stage HL
Track 10: Case: A 49-year-old man with relapsed HL receives consolidation BV after ASCT
Track 11: Design and results of the AETHERA trial of BV as consolidation therapy after ASCT for patients with HL at high risk of relapse or disease progression
Track 12: Case: A 45-year-old man with heavily pretreated HL achieves a complete response to 2 cycles of nivolumab before discontinuing therapy because of severe hepatitis
Track 13: Prevalence of PD-L1 amplification and response to immune checkpoint blockade in patients with HL
Track 14: Potential correlation between autoimmune toxicity and benefit from immune checkpoint inhibitors
Track 15: Management of autoimmune toxicities in patients receiving immune checkpoint inhibitors
Track 16: Case: A 21-year-old woman with Stage IIA nodular sclerosing classical HL and negative PET results after 2 cycles of ABVD
David J Straus, MD
Attending Physician
Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Radhakrishnan Ramchandren, MD
Professor, Hematology Oncology
Division Chief
University of Tennessee
Knoxville, Tennessee
Neil Love, MD
Research To Practice
Miami, Florida